Home Cart Sign in  
Chemical Structure| 1805789-54-1 Chemical Structure| 1805789-54-1

Structure of Samuraciclib HCl
CAS No.: 1805789-54-1

Chemical Structure| 1805789-54-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively.

Synonyms: CT7001 hydrochloride; ICEC0942 hydrochloride; Samuraciclib hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Samuraciclib HCl

CAS No. :1805789-54-1
Formula : C22H31ClN6O
M.W : 430.97
SMILES Code : O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.[H]Cl
Synonyms :
CT7001 hydrochloride; ICEC0942 hydrochloride; Samuraciclib hydrochloride
MDL No. :MFCD31657343

Safety of Samuraciclib HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Samuraciclib HCl

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF7-942R 800 nM 4 monthourss Establish ICEC0942-resistant cell line to study resistance mechanisms Oncogene. 2020 Jan;39(3):651-663
LNCaP cells 1 µM 24 h CT7001 suppressed androgen-induced AR transactivation in LNCaP cells and decreased PSA mRNA expression. Br J Cancer. 2023 Jun;128(12):2326-2337.
LNCaP cells 0.08 –0.65 µM 72 h CT7001 inhibited the growth of prostate cancer cell lines and significantly reduced the proportion of S-phase cells in LNCaP cells, while increasing the proportion of diploid (G0/G1) cells, indicating that CT7001 inhibits cell proliferation by disrupting the Rb pathway and cell cycle progression. Br J Cancer. 2023 Jun;128(12):2326-2337.
LNCaP cells 0.078 –20μM 3 h Cellular thermal shift assays (CeTSA) were conducted to investigate CT7001's target engagement in LNCaP cells, showing preferential binding to CDK7, with additional engagement of CDK2 and CDK9 at higher concentrations. Br J Cancer. 2023 Jun;128(12):2326-2337.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice C4-2B xenograft model Oral 50 mg/kg Once daily for 21 days CT7001 alone or in combination with enzalutamide significantly inhibited the growth of C4-2B xenografts, with combination therapy showing superior efficacy compared to monotherapy. Br J Cancer. 2023 Jun;128(12):2326-2337.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.60mL

2.32mL

1.16mL

23.20mL

4.64mL

2.32mL

 

Historical Records

Categories